ClinicalTrials.gg
RecruitingNCT07366944Updated Jan 26, 2026

PCOS and Problem of Eye Dryness: Is There a Benefit From Lifetyle Changes

An interventional study of exercise and limiting diet and diet limitation in Polycystic Ovary Syndrome, Dry Eye and Obesity, sponsored by Cairo University. Recruiting at 1 site in Egypt. Open to female participants aged 30 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Cairo University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
30 Years to 40 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 34 studies in Polycystic Ovary Syndrome by Cairo University — 10 open to participants now, 10 under way, none of them phase 3. Polycystic Ovary Syndrome · Cairo University.

Planned enrollment
17th of 26
40 · median 55
Started
2025
with 4 others
No phase
20 of 34
10 open now
Registered
29th of 34
by date

Among the 34 studies in Polycystic Ovary Syndrome by Cairo University, this one is the 17th largest by planned enrollment of the 26 interventional ones that give a count, is one of 5 that started in 2025, is one of 20 with no phase, and was the 29th registered.

Polycystic Ovary Syndrome

959 studies on the registry are indexed under Polycystic Ovary Syndrome; 176 are open to participants now.

Browse Polycystic Ovary Syndrome studies →

Open to participants now

10 of the 34 studies in Polycystic Ovary Syndrome by Cairo University are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 120 Polycystic Ovary Syndrome studies recruiting now, 11 (9%) set no upper age limit and 106 (88%) stop at 75 or younger; 23 take children under 18; 41 take healthy volunteers.

This study: 30 Years to 40 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 34 studies in Polycystic Ovary Syndrome by Cairo University, or all of them as a file.
02

Study summary

Women with polycystic ovarian syndrome (PCOS) may complain dryness of their eyes especially obese ones. lifestye changes are main treatrment fro both problems

Read the detailed description

Forty females with PCOS, eye dryness , and obesity will asigned to group I or Group II, n=20 for each group. Both groups will receive metformin thrice times daily and low calorie diet for 12 weeks. Group I, additionally will perform one hour of treadmill walking thrice weekly for 12 weeks.

03

Conditions studied

  • Polycystic Ovary Syndrome
  • Dry Eye
  • Obesity
04

Who can participate

Ages eligible
30 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • PCOS women
  • obese class I
  • bilateral dryness of eye

Exclusion criteria

Exclusion Criteria:

  • liver disoease
  • cardiac disease
  • renal disease
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    group number 1

    twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks. Group I, additionally will perform one hour of treadmill walking thrice weekly for 12 weeks.

    Behavioral: exercise and limiting diet

  • Active comparator
    group number 2

    Twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks.

    Behavioral: diet limitation

Interventions

  • Behavioralexercise and limiting diet

    twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks. Group I, additionally will perform one hour of treadmill walking thrice weekly for 12 weeks.

  • Behavioraldiet limitation

    twenty females with PCOS, eye dryness , and obesity will receive metformin thrice times daily and low calorie diet for 12 weeks.

06

What researchers measure

Primary outcomes

  1. schrimer test

    it is a test for assessment dye dryness

    Time frame: it will be measured after 12 weeks

Secondary outcomes

  1. Ocular surface disability index

    it is a questionaire for assessment dye dryness

    Time frame: It will be measured after 12 weeks

  2. dry eye scoring system

    it is a questionaire for assessment dye dryness

    Time frame: It will be measured after 12 weeks

  3. Tear film break-up time

    it is a test for assessment dye dryness

    Time frame: It will be measured after 12 weeks

  4. body mass index

    it will be assessed on empty stomach and bowel

    Time frame: it will be measured after 12 weeks

  5. wasit hip ratio

    it will be assessed by dividing wasit circuference on hip circumference

    Time frame: It will be measured after 12 weeks

  6. wasit circumference

    it will be assessed by tape measure

    Time frame: It will be measured after 12 weeks

  7. testesterone

    it will be assessed in serum

    Time frame: It will be measured after 12 weeks

  8. LH:FSH ratio

    The LH (Luteinizing Hormone) to FSH (Follicle-Stimulating Hormone) ratio shows the balance between these reproductive hormones

    Time frame: It will be measured after 12 weeks

  9. dehydroepiandrosterone

    it will ne assessed in serum

    Time frame: It will be measured after 12 weeks

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Jun 2026, 6 months after the start.

Of 205 non-industry interventional studies with no phase under Polycystic Ovary Syndrome, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 37. This study's planned 6 months is below that.

Counting every sponsor, half of 220 studies reached it within 17 months; a quarter within 7 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2026
First posted
Jan 26, 2026
StartActual
Dec 5, 2025
Primary completionEst.
Jun 5, 2026
CompletionEst.
Jun 5, 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07366944
Lead sponsor
Cairo University
Responsible party
Ali Mohamed Ali ismail (lecturer of physical therapy for Cardiovascular, Respiratory disorder and Geriatrics, Faculty of Physical Therapy, Cairo University, Cairo University) — Principal investigator
First posted
Jan 26, 2026
Start date
Dec 5, 2025
Primary completion
Jun 5, 2026 (estimated)
Completion
Jun 5, 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Ali MA Ismail, lecturer
Contact
ali.mohamed@pt.cu.edu.eg
01005154209
Ali Ismail
Contact
allooka2012@gmail.com
01031321109
Ali MA Ismail, lecturer
principal investigator · Cairo University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion